ACRS
Aclaris Therapeutics Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 03-17-2019 | 11-06-2018 after market close | 08-03-2018 | 05-08-2018 after market close | 03-12-2018 | 11-07-2017 | 08-08-2017 | 05-09-2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actual EPS | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -0.99 | -1.06 | -1.01 | -0.98 | -0.8 | -0.63 | -0.56 | -0.48 |
| Consensus EPS | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -1.25 | -0.95 | -0.99 | -0.9 | -0.86 | -0.68 | -0.54 |
| Estimated EPS | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -0.96 | -1.25 | -0.95 | -0.99 | -0.9 | -0.86 | -0.68 | -0.54 |
| Number of Estimates | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 3 | 3 |
| EPS Surprise | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | $0.19 | -$0.06 | $0.01 | $0.10 | $0.23 | $0.12 | $0.06 |
Stats
Summary
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
Market Cap: 759 Million
Primary Exchange: Nasdaq Global Select
Website: http://www.aclaristx.com
Shares Outstanding: 30.8 Million
Float: 29.2 Million
Dividend: 0.0 (0.0%)
Beta: 1.451529
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 3.34 Million
Ethical Flags
Longest drawdown: 502 trading days
From: 2017-04-17 To: 2019-04-18
Lowest Point:
Aclaris Therapeutics (ACRS) Presents At William Blair Late-Stage Therapeutics Conference - Slideshow
via: SeekingAlpha at 2019-04-04 12:06:04:000
The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this Read more … read more...
Aclaris Therapeutics (ACRS) Presents At William Blair Late-Stage Therapeutics Conference - Slideshow
via: SeekingAlpha at 2019-04-04 12:06:04:000
The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this Read more … read more...
Aclaris Therapeutics (ACRS) Presents At William Blair Late-Stage Therapeutics Conference - Slideshow
via: SeekingAlpha at 2019-04-04 12:06:04:000
The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this Read more … read more...
PE firms eyeing Perrigo pharma business
via: SeekingAlpha at 2019-04-04 08:27:19:000
Private equity shops Apollo Global Management and CVC Capital Partners are apparently bidding for Perrigo's ( PRGO +2.6% ) generic pharmaceuticals unit according to informed sources who add that the business could fetch more than $2.5B. More news on: Perrigo Company plc, Akorn, In… read more...
PE firms eyeing Perrigo pharma business
via: SeekingAlpha at 2019-04-04 08:27:19:000
Private equity shops Apollo Global Management and CVC Capital Partners are apparently bidding for Perrigo's ( PRGO +2.6% ) generic pharmaceuticals unit according to informed sources who add that the business could fetch more than $2.5B. More news on: Perrigo Company plc, Akorn, In… read more...
PE firms eyeing Perrigo pharma business
via: SeekingAlpha at 2019-04-04 08:27:19:000
Private equity shops Apollo Global Management and CVC Capital Partners are apparently bidding for Perrigo's ( PRGO +2.6% ) generic pharmaceuticals unit according to informed sources who add that the business could fetch more than $2.5B. More news on: Perrigo Company plc, Akorn, In… read more...
A Look At Rigel's Partnered Pipeline
via: SeekingAlpha at 2019-03-30 04:44:47:000
The year 2019 is an exciting time for Rigel Pharmaceuticals ( RIGL ) in many ways and not so much in others. On the one hand, the company will generate its first full year of sales data from Tavalisse (fostamatinib) which it began marketing for chronic immune thrombocytopenia ((ITP)) in late… read more...
A Look At Rigel's Partnered Pipeline
via: SeekingAlpha at 2019-03-30 04:44:47:000
The year 2019 is an exciting time for Rigel Pharmaceuticals ( RIGL ) in many ways and not so much in others. On the one hand, the company will generate its first full year of sales data from Tavalisse (fostamatinib) which it began marketing for chronic immune thrombocytopenia ((ITP)) in late… read more...
A Look At Rigel's Partnered Pipeline
via: SeekingAlpha at 2019-03-30 04:44:47:000
The year 2019 is an exciting time for Rigel Pharmaceuticals ( RIGL ) in many ways and not so much in others. On the one hand, the company will generate its first full year of sales data from Tavalisse (fostamatinib) which it began marketing for chronic immune thrombocytopenia ((ITP)) in late… read more...
A Look At Rigel's Partnered Pipeline
via: SeekingAlpha at 2019-03-30 04:44:47:000
The year 2019 is an exciting time for Rigel Pharmaceuticals ( RIGL ) in many ways and not so much in others. On the one hand, the company will generate its first full year of sales data from Tavalisse (fostamatinib) which it began marketing for chronic immune thrombocytopenia ((ITP)) in late… read more...
Filgotinib worth as much as $6/share to Gilead - Leerink
via: SeekingAlpha at 2019-03-29 03:55:28:000
Leerink's Geoffrey Porges likes the upside of arthritis med filgotinib for Gilead Sciences (NASDAQ: GILD ), projecting a $5 - 6/share potential bump in value. He says the JAK1 inhibitor has an 80% (unclear how he arrived at this specific figure) chance of reaching $3.7B in peak sales (how fa… read more...
Aclaris Therapeutics (ACRS) CEO Neal Walker on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 10:36:08:000
Aclaris Therapeutics (ACRS) Q4 2018 Earnings Conference Call March 18, 2019 08:00 ET Company Participants Kamil Ali-Jackson - Co-Founder and Chief Legal Officer Neal Walker - Co-Founder Chief Executive Officer, President and Director Stuart Shanler - Co-Founder and Chief Scientif… read more...
Aclaris Therapeutics (ACRS) CEO Neal Walker on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 10:36:08:000
Aclaris Therapeutics (ACRS) Q4 2018 Earnings Conference Call March 18, 2019 08:00 ET Company Participants Kamil Ali-Jackson - Co-Founder and Chief Legal Officer Neal Walker - Co-Founder Chief Executive Officer, President and Director Stuart Shanler - Co-Founder and Chief Scientif… read more...
Aclaris Therapeutics (ACRS) CEO Neal Walker on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 10:36:08:000
Aclaris Therapeutics (ACRS) Q4 2018 Earnings Conference Call March 18, 2019 08:00 ET Company Participants Kamil Ali-Jackson - Co-Founder and Chief Legal Officer Neal Walker - Co-Founder Chief Executive Officer, President and Director Stuart Shanler - Co-Founder and Chief Scientif… read more...
Healthcare names top midday movers
via: SeekingAlpha at 2019-03-18 08:46:44:000
Gainers: Dermira (NASDAQ: DERM ) +85% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +48% . Atossa Genetics (NASDAQ: ATOS ) +35% . American Midstream Partners (NYSE: AMID ) +28% . Aclaris Therapeutics (NASDAQ: ACRS ) +21% . Innovate Biopharmaceuticals (NASDAQ: INNT ) +20% . Profess… read more...
Healthcare names top midday movers
via: SeekingAlpha at 2019-03-18 08:46:44:000
Gainers: Dermira (NASDAQ: DERM ) +85% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +48% . Atossa Genetics (NASDAQ: ATOS ) +35% . American Midstream Partners (NYSE: AMID ) +28% . Aclaris Therapeutics (NASDAQ: ACRS ) +21% . Innovate Biopharmaceuticals (NASDAQ: INNT ) +20% . Profess… read more...
Healthcare names top midday movers
via: SeekingAlpha at 2019-03-18 08:46:44:000
Gainers: Dermira (NASDAQ: DERM ) +85% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +48% . Atossa Genetics (NASDAQ: ATOS ) +35% . American Midstream Partners (NYSE: AMID ) +28% . Aclaris Therapeutics (NASDAQ: ACRS ) +21% . Innovate Biopharmaceuticals (NASDAQ: INNT ) +20% . Profess… read more...
Aclaris up 22% after Q4 report/business update
via: SeekingAlpha at 2019-03-18 07:05:49:000
Aclaris Therapeutics ( ACRS +22.4% ) is up on almost 30% higher volume following its Q4 report and 2019 outlook. Highlights: More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Aclaris up 22% after Q4 report/business update
via: SeekingAlpha at 2019-03-18 07:05:49:000
Aclaris Therapeutics ( ACRS +22.4% ) is up on almost 30% higher volume following its Q4 report and 2019 outlook. Highlights: More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Aclaris up 22% after Q4 report/business update
via: SeekingAlpha at 2019-03-18 07:05:49:000
Aclaris Therapeutics ( ACRS +22.4% ) is up on almost 30% higher volume following its Q4 report and 2019 outlook. Highlights: More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Aclaris Therapeutics misses by $0.07, misses on revenue
via: SeekingAlpha at 2019-03-18 03:02:25:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q4 GAAP EPS of -$0.99 misses by $0.07 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aclaris Therapeutics misses by $0.07, misses on revenue
via: SeekingAlpha at 2019-03-18 03:02:25:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q4 GAAP EPS of -$0.99 misses by $0.07 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aclaris Therapeutics misses by $0.07, misses on revenue
via: SeekingAlpha at 2019-03-18 03:02:25:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q4 GAAP EPS of -$0.99 misses by $0.07 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aclaris Therapeutics: Buy, Sell Or Hold?
via: SeekingAlpha at 2019-01-18 13:22:18:000
Anger, resentment and jealousy doesn't change the heart of others-- it only changes yours. " - Shannon Alder Cantor Fitzgerald reissued their Buy rating and $50 price target on Aclaris Therapeutics ( ACRS ) this morning with the following commentary on the stock's prospects: We expect… read more...
Aclaris Therapeutics: Buy, Sell Or Hold?
via: SeekingAlpha at 2019-01-18 13:22:18:000
Anger, resentment and jealousy doesn't change the heart of others-- it only changes yours. " - Shannon Alder Cantor Fitzgerald reissued their Buy rating and $50 price target on Aclaris Therapeutics ( ACRS ) this morning with the following commentary on the stock's prospects: We expect… read more...
Aclaris Therapeutics: Buy, Sell Or Hold?
via: SeekingAlpha at 2019-01-18 13:22:18:000
Anger, resentment and jealousy doesn't change the heart of others-- it only changes yours. " - Shannon Alder Cantor Fitzgerald reissued their Buy rating and $50 price target on Aclaris Therapeutics ( ACRS ) this morning with the following commentary on the stock's prospects: We expect… read more...
Aclaris Therapeutics: Buy, Sell Or Hold?
via: SeekingAlpha at 2019-01-18 13:22:18:000
Anger, resentment and jealousy doesn't change the heart of others-- it only changes yours. " - Shannon Alder Cantor Fitzgerald reissued their Buy rating and $50 price target on Aclaris Therapeutics ( ACRS ) this morning with the following commentary on the stock's prospects: We expect… read more...
Aclaris Therapeutics: Buy, Sell Or Hold?
via: SeekingAlpha at 2019-01-18 13:22:18:000
Anger, resentment and jealousy doesn't change the heart of others-- it only changes yours. " - Shannon Alder Cantor Fitzgerald reissued their Buy rating and $50 price target on Aclaris Therapeutics ( ACRS ) this morning with the following commentary on the stock's prospects: We expect… read more...
Aclaris Therapeutics: Buy, Sell Or Hold?
via: SeekingAlpha at 2019-01-18 13:22:18:000
Anger, resentment and jealousy doesn't change the heart of others-- it only changes yours. " - Shannon Alder Cantor Fitzgerald reissued their Buy rating and $50 price target on Aclaris Therapeutics ( ACRS ) this morning with the following commentary on the stock's prospects: We expect… read more...
Teva outlook on stable prices buoys generics
via: SeekingAlpha at 2019-01-07 15:51:50:000
Generic drug makers are in the green after Teva Pharmaceutical Industries ( TEVA +1.9% ) chief Kre Schultz stated that he sees stable prices this year, a welcome view considering the downward pressure last year. He made the comment during his presentation at the JP Morgan Healthcare … read more...
Teva outlook on stable prices buoys generics
via: SeekingAlpha at 2019-01-07 15:51:50:000
Generic drug makers are in the green after Teva Pharmaceutical Industries ( TEVA +1.9% ) chief Kre Schultz stated that he sees stable prices this year, a welcome view considering the downward pressure last year. He made the comment during his presentation at the JP Morgan Healthcare … read more...
Teva outlook on stable prices buoys generics
via: SeekingAlpha at 2019-01-07 15:51:50:000
Generic drug makers are in the green after Teva Pharmaceutical Industries ( TEVA +1.9% ) chief Kre Schultz stated that he sees stable prices this year, a welcome view considering the downward pressure last year. He made the comment during his presentation at the JP Morgan Healthcare … read more...
Pfizer launches pivotal study of alopecia areata candidate
via: SeekingAlpha at 2019-01-03 09:20:32:000
Pfizer (NYSE: PFE ) initiates a Phase 2b/3 clinical trial evaluating Breakthrough Therapy-tagged PF-06651600, an oral JAK3 inhibitor, in patients with alopecia areata, an autoimmune disorder characterized by hair loss on the scalp, face or body. More news on: Pfizer Inc., Aclaris Thera… read more...
Pfizer launches pivotal study of alopecia areata candidate
via: SeekingAlpha at 2019-01-03 09:20:32:000
Pfizer (NYSE: PFE ) initiates a Phase 2b/3 clinical trial evaluating Breakthrough Therapy-tagged PF-06651600, an oral JAK3 inhibitor, in patients with alopecia areata, an autoimmune disorder characterized by hair loss on the scalp, face or body. More news on: Pfizer Inc., Aclaris Thera… read more...
Pfizer launches pivotal study of alopecia areata candidate
via: SeekingAlpha at 2019-01-03 09:20:32:000
Pfizer (NYSE: PFE ) initiates a Phase 2b/3 clinical trial evaluating Breakthrough Therapy-tagged PF-06651600, an oral JAK3 inhibitor, in patients with alopecia areata, an autoimmune disorder characterized by hair loss on the scalp, face or body. More news on: Pfizer Inc., Aclaris Thera… read more...
Aclaris Therapeutics up 3.5% after hours on pipeline advancement
via: SeekingAlpha at 2018-12-17 16:30:51:000
Aclaris Therapeutics (NASDAQ: ACRS ) is up 3.5% after hours on the heels of its update on its oral and topical JAK 1/3 inhibitors. More news on: Aclaris Therapeutics, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics up 3.5% after hours on pipeline advancement
via: SeekingAlpha at 2018-12-17 16:30:51:000
Aclaris Therapeutics (NASDAQ: ACRS ) is up 3.5% after hours on the heels of its update on its oral and topical JAK 1/3 inhibitors. More news on: Aclaris Therapeutics, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics up 3.5% after hours on pipeline advancement
via: SeekingAlpha at 2018-12-17 16:30:51:000
Aclaris Therapeutics (NASDAQ: ACRS ) is up 3.5% after hours on the heels of its update on its oral and topical JAK 1/3 inhibitors. More news on: Aclaris Therapeutics, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics: A Promising Dermatology Buy In 2018
via: SeekingAlpha at 2018-12-11 13:44:13:000
Headquartered in Pennsylvania, Aclaris Therapeutics ( ACRS ) is a biopharmaceutical company focused on developing novel therapies targeting various skin and hair conditions. In the third quarter, Aclaris Therapeutics missed the consensus revenue estimate by $0.12 million but beat the GAAP … read more...
Aclaris Therapeutics: A Promising Dermatology Buy In 2018
via: SeekingAlpha at 2018-12-11 13:44:13:000
Headquartered in Pennsylvania, Aclaris Therapeutics ( ACRS ) is a biopharmaceutical company focused on developing novel therapies targeting various skin and hair conditions. In the third quarter, Aclaris Therapeutics missed the consensus revenue estimate by $0.12 million but beat the GAAP … read more...
Generics under pressure on expanded price-fixing investigation
via: SeekingAlpha at 2018-12-10 12:53:46:000
The broad market's bearishness notwithstanding, generic drug makers are predominantly in the red on the news that the investigation into alleged price-fixing by state AGs now totals 47. More news on: Aceto Corporation, Aclaris Therapeutics, Akorn, Inc., Healthcare stocks news, Stocks on th… read more...
Aclaris Therapeutics (ACRS) Presents At Piper Jaffray 30th Annual Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-11-29 14:37:31:000
The following slide deck was published by Aclaris Therapeutics in conjunction with this Read more … read more...
Aclaris Therapeutics (ACRS) Presents At Piper Jaffray 30th Annual Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-11-29 14:37:31:000
The following slide deck was published by Aclaris Therapeutics in conjunction with this Read more … read more...
Aclaris Therapeutics (ACRS) Presents At Piper Jaffray 30th Annual Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-11-29 14:37:31:000
The following slide deck was published by Aclaris Therapeutics in conjunction with this Read more … read more...
Aclaris Therapeutics (ACRS) Presents At Evercore ISI HEALTHCONx Conference - Slideshow
via: SeekingAlpha at 2018-11-28 12:08:45:000
The following slide deck was published by Aclaris Therapeutics in conjunction with this Read more … read more...
Aclaris Therapeutics (ACRS) CEO Neal Walker on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-11 03:13:04:000
Aclaris Therapeutics (ACRS) Q3 2018 Earnings Conference Call November 06, 2018 05:00 PM ET Executives Kamil Ali-Jackson - Co-Founder and Chief Legal Officer Neal Walker - Co-Founder Chief Executive Officer, President and Director Stuart Shanler - Co-Founder and Chief Scientific O… read more...
Aclaris Therapeutics (ACRS) CEO Neal Walker on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-11 03:13:04:000
Aclaris Therapeutics (ACRS) Q3 2018 Earnings Conference Call November 06, 2018 05:00 PM ET Executives Kamil Ali-Jackson - Co-Founder and Chief Legal Officer Neal Walker - Co-Founder Chief Executive Officer, President and Director Stuart Shanler - Co-Founder and Chief Scientific O… read more...
Aclaris Therapeutics (ACRS) CEO Neal Walker on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-11 03:13:04:000
Aclaris Therapeutics (ACRS) Q3 2018 Earnings Conference Call November 06, 2018 05:00 PM ET Executives Kamil Ali-Jackson - Co-Founder and Chief Legal Officer Neal Walker - Co-Founder Chief Executive Officer, President and Director Stuart Shanler - Co-Founder and Chief Scientific O… read more...
Aclaris Therapeutics beats by $0.20, misses on revenue
via: SeekingAlpha at 2018-11-06 16:18:45:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q3 GAAP EPS of -$1.06 beats by $0.20 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics beats by $0.20, misses on revenue
via: SeekingAlpha at 2018-11-06 16:18:45:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q3 GAAP EPS of -$1.06 beats by $0.20 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics beats by $0.20, misses on revenue
via: SeekingAlpha at 2018-11-06 16:18:45:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q3 GAAP EPS of -$1.06 beats by $0.20 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Daily Insider Ratings Round Up 10/23/18
via: SeekingAlpha at 2018-10-25 11:49:06:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 10/23/18
via: SeekingAlpha at 2018-10-25 11:49:06:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 10/23/18
via: SeekingAlpha at 2018-10-25 11:49:06:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Premarket Losers as of 9:05 am (10/18/2018)
via: SeekingAlpha at 2018-10-18 09:12:29:000
OPGN -18% on announcing common stock offering. More news on: OpGen, Auris Medical Holding, Sealed Air Corporation, Stocks on the move, Top stock market news, , Read more … read more...
Premarket Losers as of 9:05 am (10/18/2018)
via: SeekingAlpha at 2018-10-18 09:12:29:000
OPGN -18% on announcing common stock offering. More news on: OpGen, Auris Medical Holding, Sealed Air Corporation, Stocks on the move, Top stock market news, , Read more … read more...
Premarket Losers as of 9:05 am (10/18/2018)
via: SeekingAlpha at 2018-10-18 09:12:29:000
OPGN -18% on announcing common stock offering. More news on: OpGen, Auris Medical Holding, Sealed Air Corporation, Stocks on the move, Top stock market news, , Read more … read more...
Aclaris prices stock offering at $10.75; shares down 12% premarket
via: SeekingAlpha at 2018-10-18 07:01:14:000
Aclaris Therapeutics (NASDAQ: ACRS ) prices its public offering of 8.645M common shares at $10.75 per share. Underwriters over-allotment is an additional ~1.297M shares. Closing date is October 22. More news on: Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read m… read more...
Aclaris prices stock offering at $10.75; shares down 12% premarket
via: SeekingAlpha at 2018-10-18 07:01:14:000
Aclaris Therapeutics (NASDAQ: ACRS ) prices its public offering of 8.645M common shares at $10.75 per share. Underwriters over-allotment is an additional ~1.297M shares. Closing date is October 22. More news on: Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read m… read more...
Aclaris prices stock offering at $10.75; shares down 12% premarket
via: SeekingAlpha at 2018-10-18 07:01:14:000
Aclaris Therapeutics (NASDAQ: ACRS ) prices its public offering of 8.645M common shares at $10.75 per share. Underwriters over-allotment is an additional ~1.297M shares. Closing date is October 22. More news on: Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read m… read more...
After Hours Gainers / Losers (10/17/2018)
via: SeekingAlpha at 2018-10-17 17:35:09:000
Top Gainers: PTI +32.2% . AA +5.6% . CIFS +4.3% . GPOR +3.3% . More news on: Proteostasis Therapeutics, Alcoa Corporation, China Internet Nationwide Financial Services Inc., Stocks on the move, , News on ETFs, Top stock market news, Read more …... read more...
Aclaris acquires rosacea cream from Allergan for $65M
via: SeekingAlpha at 2018-10-15 16:10:40:000
Aclaris Therapeutics (NASDAQ: ACRS ) has agreed to acquire global rights to Allergan's (NYSE: AGN ) RHOFADE (oxymetazoline hydrochloride) cream 1%, indicated for the topical treatment of facial redness associated with rosacea in adults. More news on: Aclaris Therapeutics, Allergan plc, H… read more...
Aclaris acquires rosacea cream from Allergan for $65M
via: SeekingAlpha at 2018-10-15 16:10:40:000
Aclaris Therapeutics (NASDAQ: ACRS ) has agreed to acquire global rights to Allergan's (NYSE: AGN ) RHOFADE (oxymetazoline hydrochloride) cream 1%, indicated for the topical treatment of facial redness associated with rosacea in adults. More news on: Aclaris Therapeutics, Allergan plc, H… read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-05 08:59:38:000
Noteworthy events during the week of October 7 - 13 for healthcare investors. More news on: Inspire Medical Systems, Inc., OptiNose, Inc., Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-05 08:59:38:000
Noteworthy events during the week of October 7 - 13 for healthcare investors. More news on: Inspire Medical Systems, Inc., OptiNose, Inc., Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-05 08:59:38:000
Noteworthy events during the week of October 7 - 13 for healthcare investors. More news on: Inspire Medical Systems, Inc., OptiNose, Inc., Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-05 08:59:38:000
Noteworthy events during the week of October 7 - 13 for healthcare investors. More news on: Inspire Medical Systems, Inc., OptiNose, Inc., Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-05 08:59:38:000
Noteworthy events during the week of October 7 - 13 for healthcare investors. More news on: Inspire Medical Systems, Inc., OptiNose, Inc., Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Generics in the green following proposed favorable guidance from FDA
via: SeekingAlpha at 2018-10-02 14:03:56:000
Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...
Generics in the green following proposed favorable guidance from FDA
via: SeekingAlpha at 2018-10-02 14:03:56:000
Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...
Generics in the green following proposed favorable guidance from FDA
via: SeekingAlpha at 2018-10-02 14:03:56:000
Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...
Aclaris Therapeutics announces phase 3 studies evaluating A-101 45% in patients with common warts
via: SeekingAlpha at 2018-09-24 09:31:21:000
Aclaris Therapeutics ( ACRS ) announced the initiation of a Phase 3 wart program primarily evaluating A-101 (hydrogen peroxide) topical solution 45% (A-101 45%) in patients with common warts. More news on: Aclaris Therapeutics, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics announces phase 3 studies evaluating A-101 45% in patients with common warts
via: SeekingAlpha at 2018-09-24 09:31:21:000
Aclaris Therapeutics ( ACRS ) announced the initiation of a Phase 3 wart program primarily evaluating A-101 (hydrogen peroxide) topical solution 45% (A-101 45%) in patients with common warts. More news on: Aclaris Therapeutics, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics announces phase 3 studies evaluating A-101 45% in patients with common warts
via: SeekingAlpha at 2018-09-24 09:31:21:000
Aclaris Therapeutics ( ACRS ) announced the initiation of a Phase 3 wart program primarily evaluating A-101 (hydrogen peroxide) topical solution 45% (A-101 45%) in patients with common warts. More news on: Aclaris Therapeutics, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 14:29:15:000
Aclaris Therapeutics, Inc. (ACRS) Q2 2018 Earnings Conference Call August 03, 2018 18:00 P.M. ET Executives Kamil Ali-Jackson - CLO and Corporate Secretary Neal Walker - President and CEO Brett Fair - Chief Commercial Officer Stuart D. Shanler - Chief Scientific Officer Frank… read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 14:29:15:000
Aclaris Therapeutics, Inc. (ACRS) Q2 2018 Earnings Conference Call August 03, 2018 18:00 P.M. ET Executives Kamil Ali-Jackson - CLO and Corporate Secretary Neal Walker - President and CEO Brett Fair - Chief Commercial Officer Stuart D. Shanler - Chief Scientific Officer Frank… read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 14:29:15:000
Aclaris Therapeutics, Inc. (ACRS) Q2 2018 Earnings Conference Call August 03, 2018 18:00 P.M. ET Executives Kamil Ali-Jackson - CLO and Corporate Secretary Neal Walker - President and CEO Brett Fair - Chief Commercial Officer Stuart D. Shanler - Chief Scientific Officer Frank… read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 14:29:15:000
Aclaris Therapeutics, Inc. (ACRS) Q2 2018 Earnings Conference Call August 03, 2018 18:00 P.M. ET Executives Kamil Ali-Jackson - CLO and Corporate Secretary Neal Walker - President and CEO Brett Fair - Chief Commercial Officer Stuart D. Shanler - Chief Scientific Officer Frank… read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 14:29:15:000
Aclaris Therapeutics, Inc. (ACRS) Q2 2018 Earnings Conference Call August 03, 2018 18:00 P.M. ET Executives Kamil Ali-Jackson - CLO and Corporate Secretary Neal Walker - President and CEO Brett Fair - Chief Commercial Officer Stuart D. Shanler - Chief Scientific Officer Frank… read more...
Aclaris reports Q2 results
via: SeekingAlpha at 2018-08-03 08:33:00:000
Aclaris Therapeutics ( ACRS ) Q2 results : Revenues: $3.7M; ESKATA product sales: $1.5M; Contract research: $1.1M; Other revenue: $1M. More news on: Aclaris Therapeutics, Healthcare stocks news, Earnings news and commentary, Read more … read more...
Aclaris reports Q2 results
via: SeekingAlpha at 2018-08-03 08:33:00:000
Aclaris Therapeutics ( ACRS ) Q2 results : Revenues: $3.7M; ESKATA product sales: $1.5M; Contract research: $1.1M; Other revenue: $1M. More news on: Aclaris Therapeutics, Healthcare stocks news, Earnings news and commentary, Read more … read more...
Aclaris reports Q2 results
via: SeekingAlpha at 2018-08-03 08:33:00:000
Aclaris Therapeutics ( ACRS ) Q2 results : Revenues: $3.7M; ESKATA product sales: $1.5M; Contract research: $1.1M; Other revenue: $1M. More news on: Aclaris Therapeutics, Healthcare stocks news, Earnings news and commentary, Read more … read more...
Aclaris reports Q2 results
via: SeekingAlpha at 2018-08-03 08:33:00:000
Aclaris Therapeutics ( ACRS ) Q2 results : Revenues: $3.7M; ESKATA product sales: $1.5M; Contract research: $1.1M; Other revenue: $1M. More news on: Aclaris Therapeutics, Healthcare stocks news, Earnings news and commentary, Read more … read more...
Aclaris reports Q2 results
via: SeekingAlpha at 2018-08-03 08:33:00:000
Aclaris Therapeutics ( ACRS ) Q2 results : Revenues: $3.7M; ESKATA product sales: $1.5M; Contract research: $1.1M; Other revenue: $1M. More news on: Aclaris Therapeutics, Healthcare stocks news, Earnings news and commentary, Read more … read more...
Aclaris Therapeutics beats by $0.08, beats on revenue
via: SeekingAlpha at 2018-08-03 07:03:24:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q2 EPS of -$1.01 beats by $0.08 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics beats by $0.08, beats on revenue
via: SeekingAlpha at 2018-08-03 07:03:24:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q2 EPS of -$1.01 beats by $0.08 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics beats by $0.08, beats on revenue
via: SeekingAlpha at 2018-08-03 07:03:24:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q2 EPS of -$1.01 beats by $0.08 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics beats by $0.08, beats on revenue
via: SeekingAlpha at 2018-08-03 07:03:24:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q2 EPS of -$1.01 beats by $0.08 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics beats by $0.08, beats on revenue
via: SeekingAlpha at 2018-08-03 07:03:24:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q2 EPS of -$1.01 beats by $0.08 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
3 Things In Biotech, June 10: Can CTI Salvage Bad News?
via: SeekingAlpha at 2018-07-10 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. CTI Biopharma falters in non-Hodgkin lymphoma Company: CTI Biopharma ( CTIC ) Therapy: Pi… read more...
3 Things In Biotech, June 10: Can CTI Salvage Bad News?
via: SeekingAlpha at 2018-07-10 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. CTI Biopharma falters in non-Hodgkin lymphoma Company: CTI Biopharma ( CTIC ) Therapy: Pi… read more...
3 Things In Biotech, June 10: Can CTI Salvage Bad News?
via: SeekingAlpha at 2018-07-10 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. CTI Biopharma falters in non-Hodgkin lymphoma Company: CTI Biopharma ( CTIC ) Therapy: Pi… read more...
Aclaris Therapeutics expands leadership team
via: SeekingAlpha at 2018-06-15 07:55:30:000
Aclaris Therapeutics (NASDAQ: ACRS ) expands its executive leadership team with the appointment of David Gordon, MB ChB, as Chief Medical Officer. Dr. Gordon will report to President and CEO, Dr. Neal Walker, and will lead Aclaris clinical research and medical affairs functions. … read more...
Aclaris Therapeutics expands leadership team
via: SeekingAlpha at 2018-06-15 07:55:30:000
Aclaris Therapeutics (NASDAQ: ACRS ) expands its executive leadership team with the appointment of David Gordon, MB ChB, as Chief Medical Officer. Dr. Gordon will report to President and CEO, Dr. Neal Walker, and will lead Aclaris clinical research and medical affairs functions. … read more...
Aclaris Therapeutics expands leadership team
via: SeekingAlpha at 2018-06-15 07:55:30:000
Aclaris Therapeutics (NASDAQ: ACRS ) expands its executive leadership team with the appointment of David Gordon, MB ChB, as Chief Medical Officer. Dr. Gordon will report to President and CEO, Dr. Neal Walker, and will lead Aclaris clinical research and medical affairs functions. … read more...
Aclaris Therapeutics expands leadership team
via: SeekingAlpha at 2018-06-15 07:55:30:000
Aclaris Therapeutics (NASDAQ: ACRS ) expands its executive leadership team with the appointment of David Gordon, MB ChB, as Chief Medical Officer. Dr. Gordon will report to President and CEO, Dr. Neal Walker, and will lead Aclaris clinical research and medical affairs functions. … read more...
Aclaris Therapeutics expands leadership team
via: SeekingAlpha at 2018-06-15 07:55:30:000
Aclaris Therapeutics (NASDAQ: ACRS ) expands its executive leadership team with the appointment of David Gordon, MB ChB, as Chief Medical Officer. Dr. Gordon will report to President and CEO, Dr. Neal Walker, and will lead Aclaris clinical research and medical affairs functions. … read more...
After Hours Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 17:35:34:000
Top gainers: CRON +2.3% . LGCY +1.9% . TISI +1.7% . NCSM +1.5% . BCOV +1.5% . More news on: Cronos Group, Inc., Legacy Reserves LP, Team, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 17:35:34:000
Top gainers: CRON +2.3% . LGCY +1.9% . TISI +1.7% . NCSM +1.5% . BCOV +1.5% . More news on: Cronos Group, Inc., Legacy Reserves LP, Team, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 17:35:34:000
Top gainers: CRON +2.3% . LGCY +1.9% . TISI +1.7% . NCSM +1.5% . BCOV +1.5% . More news on: Cronos Group, Inc., Legacy Reserves LP, Team, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 17:35:34:000
Top gainers: CRON +2.3% . LGCY +1.9% . TISI +1.7% . NCSM +1.5% . BCOV +1.5% . More news on: Cronos Group, Inc., Legacy Reserves LP, Team, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 17:35:34:000
Top gainers: CRON +2.3% . LGCY +1.9% . TISI +1.7% . NCSM +1.5% . BCOV +1.5% . More news on: Cronos Group, Inc., Legacy Reserves LP, Team, Inc., Stocks on the move, , News on ETFs, Read more … read more...
Verrica Pharmaceuticals Aims For $75 Million U.S. IPO
via: SeekingAlpha at 2018-06-07 11:37:54:000
Quick Take Verrica Pharmaceuticals ( VRCA ) intends to raise $75 million in an IPO of its common stock, per an SEC filing . The company is developing a range of treatment candidates for various skin diseases. VRCA is in Phase 3 trials for its lead candidate and expects to publish topl… read more...
Your Daily Pharma Scoop: Crispr On Hold, AstraZeneca Stumbles Again, TherapeuticsMD Receives FDA Approval
via: SeekingAlpha at 2018-05-31 18:00:00:000
Analysis Focus: CRSP Crispr Therapeutics (CRSP) is one of the three companies that specialises in CRISPR-Cas9 genome editing technique. All three companies had spectacular IPOs but presently Crispr Therapeutics is the only one that has retained the initial euphoria and has become a $3.472B… read more...
Your Daily Pharma Scoop: Crispr On Hold, AstraZeneca Stumbles Again, TherapeuticsMD Receives FDA Approval
via: SeekingAlpha at 2018-05-31 18:00:00:000
Analysis Focus: CRSP Crispr Therapeutics (CRSP) is one of the three companies that specialises in CRISPR-Cas9 genome editing technique. All three companies had spectacular IPOs but presently Crispr Therapeutics is the only one that has retained the initial euphoria and has become a $3.472B… read more...
Your Daily Pharma Scoop: Crispr On Hold, AstraZeneca Stumbles Again, TherapeuticsMD Receives FDA Approval
via: SeekingAlpha at 2018-05-31 18:00:00:000
Analysis Focus: CRSP Crispr Therapeutics (CRSP) is one of the three companies that specialises in CRISPR-Cas9 genome editing technique. All three companies had spectacular IPOs but presently Crispr Therapeutics is the only one that has retained the initial euphoria and has become a $3.472B… read more...
Verrica Pharmaceuticals Files For $86 Million IPO
via: SeekingAlpha at 2018-05-30 17:22:39:000
Quick Take Verrica Pharmaceuticals ( VRCA ) intends to sell shares of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapies for common skin diseases. The companys current focus is dev… read more...
Verrica Pharmaceuticals Files For $86 Million IPO
via: SeekingAlpha at 2018-05-30 17:22:39:000
Quick Take Verrica Pharmaceuticals ( VRCA ) intends to sell shares of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapies for common skin diseases. The companys current focus is dev… read more...
Verrica Pharmaceuticals Files For $86 Million IPO
via: SeekingAlpha at 2018-05-30 17:22:39:000
Quick Take Verrica Pharmaceuticals ( VRCA ) intends to sell shares of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapies for common skin diseases. The companys current focus is dev… read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-13 00:42:11:000
Aclaris Therapeutics, Inc. (ACRS) Q1 2018 Earnings Conference Call May 08, 2018, 17:00 ET Executives Kamil Ali-Jackson - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary Neal Walker - Co-Founder, CEO, President & Director Brett Fair - Chief Commercial… read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-13 00:42:11:000
Aclaris Therapeutics, Inc. (ACRS) Q1 2018 Earnings Conference Call May 08, 2018, 17:00 ET Executives Kamil Ali-Jackson - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary Neal Walker - Co-Founder, CEO, President & Director Brett Fair - Chief Commercial… read more...
Aclaris Therapeutics beats by $0.02, beats on revenue
via: SeekingAlpha at 2018-05-08 16:20:47:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q1 EPS of -$0.98 beats by $0.02 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics beats by $0.02, beats on revenue
via: SeekingAlpha at 2018-05-08 16:20:47:000
Aclaris Therapeutics (NASDAQ: ACRS ): Q1 EPS of -$0.98 beats by $0.02 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
via: SeekingAlpha at 2018-04-24 08:00:00:000
Analysis focus: Roche Today we will discuss Roche (RHHBY), after the company announced data with its multiple sclerosis ((MS)) treatment Ocrevus from a long-term extension study. Ocrevus has seen strong uptake since its launch last year, and is expected to be a key value driver… read more...
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
via: SeekingAlpha at 2018-04-24 08:00:00:000
Analysis focus: Roche Today we will discuss Roche (RHHBY), after the company announced data with its multiple sclerosis ((MS)) treatment Ocrevus from a long-term extension study. Ocrevus has seen strong uptake since its launch last year, and is expected to be a key value driver… read more...
Mid-stage study underway for Aclaris' ATI-502 for inherited hair loss
via: SeekingAlpha at 2018-04-23 11:08:30:000
The first patient has been dosed in an open-label Phase 2 clinical trial assessing Aclaris Therapeutics' ( ACRS +0.2% ) topical ATI-502 for the treatment of androgenic alopecia, also known as male-pattern baldness (although women have it as well). More news on: Aclaris Therapeutics, … read more...
Mid-stage study underway for Aclaris' ATI-502 for inherited hair loss
via: SeekingAlpha at 2018-04-23 11:08:30:000
The first patient has been dosed in an open-label Phase 2 clinical trial assessing Aclaris Therapeutics' ( ACRS +0.2% ) topical ATI-502 for the treatment of androgenic alopecia, also known as male-pattern baldness (although women have it as well). More news on: Aclaris Therapeutics, … read more...
BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved
via: SeekingAlpha at 2018-04-10 03:18:01:000
I met the towering intellectuals in books, not in the classroom, which is natural. I cant remember when I first read Ben Franklin. I had Thomas Jefferson over my bed at seven or eight. My family was into all that stuff, getting ahead through discipline, knowledge, and self-control…. read more...
BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved
via: SeekingAlpha at 2018-04-10 03:18:01:000
I met the towering intellectuals in books, not in the classroom, which is natural. I cant remember when I first read Ben Franklin. I had Thomas Jefferson over my bed at seven or eight. My family was into all that stuff, getting ahead through discipline, knowledge, and self-control…. read more...
Your Daily Pharma Scoop: Major Setback For Incyte, Aclaris Agreement, MannKind Offering
via: SeekingAlpha at 2018-04-07 08:03:00:000
A nalysis focus: Incyte Incyte (INCY) shares tumbled more than 17% as investors digested the disappointing news with regard to the companys phase 3 study evaluating the Epacadostat/Keytruda combination in patients with unresectable or metastatic melanoma. The randomize… read more...
Your Daily Pharma Scoop: Major Setback For Incyte, Aclaris Agreement, MannKind Offering
via: SeekingAlpha at 2018-04-07 08:03:00:000
A nalysis focus: Incyte Incyte (INCY) shares tumbled more than 17% as investors digested the disappointing news with regard to the companys phase 3 study evaluating the Epacadostat/Keytruda combination in patients with unresectable or metastatic melanoma. The randomize… read more...
Aclaris Therapeutics partners with Cipher Pharmaceuticals to commercialize A-101 40% for the treatment of raised seborrheic keratoses in Canada
via: SeekingAlpha at 2018-04-06 07:22:11:000
Aclaris Therapeutics (NASDAQ: ACRS ) has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals (NASDAQ: CPHR ). More news on: Aclaris Therapeutics, Cipher Pharmaceuticals, Inc., Heal… read more...
Aclaris Therapeutics partners with Cipher Pharmaceuticals to commercialize A-101 40% for the treatment of raised seborrheic keratoses in Canada
via: SeekingAlpha at 2018-04-06 07:22:11:000
Aclaris Therapeutics (NASDAQ: ACRS ) has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals (NASDAQ: CPHR ). More news on: Aclaris Therapeutics, Cipher Pharmaceuticals, Inc., Heal… read more...
Concert Therapeutics Will See A Second Wind In Coming Months
via: SeekingAlpha at 2018-04-02 10:05:34:000
Concert Therapeutics ( CNCE ) is a great long opportunity for investors in the biotechnology industry. The small-cap company has seen a 32% rise in the past year, but potential longs should not consider the opportunity missed. A brief look into Concert's pipeline and financial structure wi… read more...
Concert Therapeutics Will See A Second Wind In Coming Months
via: SeekingAlpha at 2018-04-02 10:05:34:000
Concert Therapeutics ( CNCE ) is a great long opportunity for investors in the biotechnology industry. The small-cap company has seen a 32% rise in the past year, but potential longs should not consider the opportunity missed. A brief look into Concert's pipeline and financial structure wi… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-03-28 08:39:34:000
Dicerna Pharmaceuticals (NASDAQ: DRNA ) initiated with Neutral rating and $10 (9% downside risk) price target at B. Riley FBR. More news on: Dicerna Pharmaceuticals, Inc., Clementia Pharmaceuticals, Regulus Therapeutics, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-03-28 08:39:34:000
Dicerna Pharmaceuticals (NASDAQ: DRNA ) initiated with Neutral rating and $10 (9% downside risk) price target at B. Riley FBR. More news on: Dicerna Pharmaceuticals, Inc., Clementia Pharmaceuticals, Regulus Therapeutics, Healthcare stocks news, Read more … read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-03-12 16:24:06:000
Aclaris Therapeutics, Inc. (ACRS) Q4 2017 Results Earnings Conference Call March 12, 2018 08:00 AM ET Executives Kamil Jackson - Chief Legal Officer Neal Walker - President and CEO Chris Powala - Chief Regulatory Officer and Chief Development Officer Stuart Shanler - Chief Scie… read more...
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-03-12 16:24:06:000
Aclaris Therapeutics, Inc. (ACRS) Q4 2017 Results Earnings Conference Call March 12, 2018 08:00 AM ET Executives Kamil Jackson - Chief Legal Officer Neal Walker - President and CEO Chris Powala - Chief Regulatory Officer and Chief Development Officer Stuart Shanler - Chief Scie… read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-09 08:15:07:000
Pulmatrix (NASDAQ: PULM ) initiated with Buy rating and $5 (228% upside) price target at H.C. Wainwright. More news on: Pulmatrix, Inc., Aquinox Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-09 08:15:07:000
Pulmatrix (NASDAQ: PULM ) initiated with Buy rating and $5 (228% upside) price target at H.C. Wainwright. More news on: Pulmatrix, Inc., Aquinox Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-09 08:15:07:000
Pulmatrix (NASDAQ: PULM ) initiated with Buy rating and $5 (228% upside) price target at H.C. Wainwright. More news on: Pulmatrix, Inc., Aquinox Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-09 08:15:07:000
Pulmatrix (NASDAQ: PULM ) initiated with Buy rating and $5 (228% upside) price target at H.C. Wainwright. More news on: Pulmatrix, Inc., Aquinox Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-09 08:15:07:000
Pulmatrix (NASDAQ: PULM ) initiated with Buy rating and $5 (228% upside) price target at H.C. Wainwright. More news on: Pulmatrix, Inc., Aquinox Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...
U.S. Justice Department may seek damages from generic drugmakers for price-fixing
via: SeekingAlpha at 2018-01-19 13:16:00:000
Some generic drug firms are under modest pressure in apparent response to a speech delivered by U.S. Department of Justice antitrust division chief Makan Delrahim earlier today at George Mason University's law school. He said the DOJ may sue generic drug companies to recover damages over all… read more...
Wall Street Breakfast: Investors Calm As Government Shutdown Looms
via: SeekingAlpha at 2018-01-19 07:01:29:000
Markets appear to be shrugging off the potential for a government shutdown as traders are reminded that nearly $6.9T has been added to the U.S. stock market cap over the last year (President Trump will celebrate his inauguration anniversary tomorrow). Though House Republicans have v… read more...
Generic firms under pressure on possible hospital drug-making venture
via: SeekingAlpha at 2018-01-18 10:06:04:000
Generic drug makers are under pressure in early trading on the heels of a New York Times article about hospital groups' plans to establish a non-profit drug company aimed at supplying certain generic drugs at affordable prices. More news on: Amphastar, ANI Pharmaceuticals, Inc., Aclaris Th… read more...
Hospital groups planning to enter generic drugs business
via: SeekingAlpha at 2018-01-18 08:21:15:000
The NYT reports that some U.S. hospital systems are planning to enter the generic drugs business in an effort to preserve the supply of key off-patent medicines at affordable prices. About 300 hospitals, led by Utah-based Intermountain Healthcare, are on board with more to follow. More n… read more...
Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback
via: SeekingAlpha at 2018-01-10 01:14:42:000
Analysis of top Seeking Alpha coverage: Aradigm Today we will discuss the much-anticipated FDA briefing documents for Aradaigms ( ARDM ) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11 th . Following the release of the docu… read more...
FDA advancing plan to streamline generic drug reviews
via: SeekingAlpha at 2018-01-03 12:54:23:000
The FDA released two documents today aimed at making the generic drug application and review process more efficient, the aim of its Drug Competition Action Plan. More news on: Amphastar, ANI Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...
Aclaris Therapeutics initiates a clinical trial to study ATI-50002 Topical in patients with vitiligo
via: SeekingAlpha at 2017-12-19 08:35:20:000
Aclaris Therapeutics(NASDAQ: ACRS ) initiates a Phase 2 open-label clinical trial of ATI-50002, a topical Janus Kinase 1/3 inhibitor and an investigational drug, for treatment of non-segmental vitiligo of the face. More news on: Aclaris Therapeutics, Healthcare stocks news, R… read more...
Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering
via: SeekingAlpha at 2017-12-19 08:04:09:000
Content Analysis of coverage: RARE Stocks in the news: REGN, MDGL Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Subscriber Questions & Answers (for TPT Subscribers only) Catalyst Rundown (for… read more...
Aclaris - FDA Approved Its First Drug, And What Now?
via: SeekingAlpha at 2017-12-18 16:15:31:000
Introduction The value of a company that is not (yet) generating profit is in the eyes of the beholders. There are often too many variables for anyone to confidently and credibly say the exact value of a yet-to-be-profitable company. Nevertheless, it does not prevent some contributor… read more...
3 Things In Biotech You Should Learn Today: December 18, 2017
via: SeekingAlpha at 2017-12-18 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. If you haven't had a chance to check it out yet, I hope you'll consider giving my recent wr… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|